Burosumab: First Global Approval
- 20 April 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 78 (6), 707-714
- https://doi.org/10.1007/s40265-018-0905-7
Abstract
Burosumab (Crysvita®; Kyowa Hakko Kirin Co., Ltd. and Ultragenyx Pharmaceutical Inc.) is a fully human monoclonal antibody directed at fibroblast growth factor 23 (FGF23). Excessive FGF23 production has been implicated in various hypophosphataemic diseases. Inhibition of FGF23 by burosumab results in increased renal phosphate reabsorption and increased serum levels of phosphorus and active vitamin D. In February 2018, the EMA granted subcutaneous burosumab conditional marketing authorization for the treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. In April 2018, the US FDA approved burosumab for the treatment of XLH in adults and children one year of age and older. Multinational phase III trials of burosumab are currently underway in adult and paediatric patients with XLH. Burosumab is also being evaluated in the phase II setting in adults with tumour-induced osteomalacia and epidermal nevus syndrome in the USA, as well as in Japan and Korea. This article summarizes the milestones in the development of burosumab leading to its first global approval in the EU for XLH in paediatric patients.Keywords
This publication has 9 references indexed in Scilit:
- Population pharmacokinetic and pharmacodynamic analyses from a 4‐month intradose escalation and its subsequent 12‐month dose titration studies for a human monoclonal anti‐FGF23 antibody (KRN23) in adults with X‐linked hypophosphatemiaThe Journal of Clinical Pharmacology, 2015
- Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemiaThe Journal of Clinical Pharmacology, 2015
- Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.Journal of Clinical Endocrinology & Metabolism, 2015
- Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatmentEndocrine Journal, 2015
- Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.JCI Insight, 2014
- Rickets: Part IIPediatric Radiology, 2012
- Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/OsteomalaciaJournal of Bone and Mineral Research, 2009
- Incidence and prevalence of nutritional and hereditary rickets in southern DenmarkActa Endocrinologica, 2009
- NEW PERSPECTIVES ON THE BIOLOGY AND TREATMENT OF X-LINKED HYPOPHOSPHATEMIC RICKETSPediatric Clinics of North America, 1997